EP2338911B1 - Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells - Google Patents
Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells Download PDFInfo
- Publication number
- EP2338911B1 EP2338911B1 EP20100013146 EP10013146A EP2338911B1 EP 2338911 B1 EP2338911 B1 EP 2338911B1 EP 20100013146 EP20100013146 EP 20100013146 EP 10013146 A EP10013146 A EP 10013146A EP 2338911 B1 EP2338911 B1 EP 2338911B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- expression
- recombinant
- cell line
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010006519 Molecular Chaperones Proteins 0.000 title claims description 82
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims description 77
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims description 77
- 102000005431 Molecular Chaperones Human genes 0.000 title claims description 71
- 238000004519 manufacturing process Methods 0.000 title claims description 32
- 210000004962 mammalian cell Anatomy 0.000 title claims description 19
- 210000004027 cell Anatomy 0.000 claims description 221
- 239000013604 expression vector Substances 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 86
- 108090000623 proteins and genes Proteins 0.000 claims description 81
- 230000014509 gene expression Effects 0.000 claims description 78
- 102000004169 proteins and genes Human genes 0.000 claims description 73
- 102100032859 Protein AMBP Human genes 0.000 claims description 63
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 47
- 102000001690 Factor VIII Human genes 0.000 claims description 36
- 108020002326 glutamine synthetase Proteins 0.000 claims description 36
- 108010054218 Factor VIII Proteins 0.000 claims description 35
- 102000005396 glutamine synthetase Human genes 0.000 claims description 35
- 102000004082 Calreticulin Human genes 0.000 claims description 33
- 108090000549 Calreticulin Proteins 0.000 claims description 33
- 230000001747 exhibiting effect Effects 0.000 claims description 17
- 230000001131 transforming effect Effects 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 9
- 230000010354 integration Effects 0.000 claims description 4
- 102100029968 Calreticulin Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 123
- 239000000047 product Substances 0.000 description 44
- 101800001691 Inter-alpha-trypsin inhibitor light chain Proteins 0.000 description 42
- 239000012634 fragment Substances 0.000 description 39
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 38
- 108010056891 Calnexin Proteins 0.000 description 30
- 102100021868 Calnexin Human genes 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 25
- 229960000301 factor viii Drugs 0.000 description 25
- 238000001890 transfection Methods 0.000 description 17
- 230000028327 secretion Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000009466 transformation Effects 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 12
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- -1 Erp57 Proteins 0.000 description 11
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 11
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 10
- 230000003248 secreting effect Effects 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 238000010367 cloning Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 229950010131 puromycin Drugs 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 101150115114 dnaJ gene Proteins 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108020003519 protein disulfide isomerase Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 2
- 101710106224 Protein disulfide-isomerase A3 Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000031852 maintenance of location in cell Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- SXTAYKAGBXMACB-UHFFFAOYSA-N methionine sulfoximine Chemical compound CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000898052 Homo sapiens Calnexin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000016227 Protein disulphide isomerases Human genes 0.000 description 1
- 108050004742 Protein disulphide isomerases Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- IAKHMKGGTNLKSZ-UHFFFAOYSA-N colchicine Chemical compound C1CC(NC(C)=O)C2=CC(=O)C(OC)=CC=C2C2=C1C=C(OC)C(OC)=C2OC IAKHMKGGTNLKSZ-UHFFFAOYSA-N 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000057386 human CANX Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- QNTJKRDAWNRWRV-UHFFFAOYSA-M methyl sulfate;trimethyl(propyl)azanium Chemical compound COS([O-])(=O)=O.CCC[N+](C)(C)C QNTJKRDAWNRWRV-UHFFFAOYSA-M 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/07—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Definitions
- the present invention relates to the general field of recombinant protein production in a mammalian host cell. Specifically, the present invention relates to enhanced production of a recombinant bikunin or Factor VIII protein by coexpressing at least one Erp57 chaperone protein in the mammalian host cell.
- molecular chaperone proteins catalyze disulfide bond exchange and assist in the proper folding of newly synthesized proteins. This observation has led to a large number of studies and proposed uses for these quality control proteins. For example, increasing pDI (protein disulfide isomerase) activity in bacterial, yeast and insect cell expression systems can have beneficial effects on protein solubility and folding and, in some cases, can lead to an increase in the secretion of heterologous proteins (1-7).
- pDI protein disulfide isomerase
- Molecular chaperones have not had the same level of success on recombinant protein expression and secretion in mammalian cell systems.
- overexpression of the pDI chaperone in Chinese hamster ovary (CHO) cells not only had no effect on the secretion levels of IL-15, but also caused a decrease in secretion, and an increase in cellular retention of a tumor necrosis factor receptor-Fc fusion protein (TNFR:Fc) (13).
- TNFR:Fc tumor necrosis factor receptor-Fc fusion protein
- Other studies have shown that overexpression of the BiP chaperone in mammalian cells can lead to increased cellular retention and decreased secretion of recombinant proteins (14-15 and U.S. Patent No. 4,912,040 ).
- the regulatory mechanisms involved in protein processing within the mammalian cell are complex, and probably involve the cooperation of many of these chaperone proteins. Therefore, one cannot predict whether a particular chaperone will lead to an increase in the production of a certain
- the '597 patent does not enable one of skill in the art to use chaperones to improve the production and secretion of a recombinant protein in eukaryotic cells.
- the state of art does not teach one to predict what effect a particular chaperone will have in the production and secretion of a given recombinant protein in cell culture models such as those described herein. The applicants were therefore surprised to find that when the chaperones described in this study were transfected into mammalian cell lines expressing a secreted, recombinant protein, the resultant effect was an overall increase in the production of the secreted protein.
- a mammalian CHO host cell for enhanced expression of a recombinant bikunin protein having genetic material coding for expression of said recombinant bikunin protein and transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- the recombinant protein product is secreted.
- the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- a method for producing a mammalian CHO host cell for enhanced expression of a recombinant bikunin protein comprises providing a mammalian CHO cell having genetic material coding for expression of recombinant bikunin protein; and transforming the mammalian CHO cell with at least one expression vector comprising DNA encoding a chaperone protein Erp57.
- the recombinant protein product is secreted.
- the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- a method for producing a secreted recombinant protein product comprising the steps of: culturing a mammalian host cell of claim 1 or claim 2, and recovering from the culture medium the recombinant protein so produced and secreted.
- the recombinant protein product is secreted.
- the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- a method for enhancing yield of a recombinant bikunin protein comprising the steps of: inserting at least one chaperone protein expression vector comprising DNA incoding Erp57 chaperone protein into said first cell line so as to form a modified cell line; and selecting from said modified cell line at least one second cell line exhibiting enhanced yield of the recombinant protein.
- the recombinant protein product is secreted.
- the genetic material coding for expression of said recombinant protein product is integrated into the first cell line DNA.
- the second cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- At least one second cell line is produced from said first cell line by selecting a portion of said first cell line exhibiting integration of the chaperone protein expression vector into host DNA.
- Also disclosed is a method for enhancing yield of a recombinant protein or fragment thereof in a mammalian cell comprises introducing genetic material coding for a recombinant protein or fragment thereof into a cell line exhibiting enhanced chaperone protein expression.
- the recombinant protein product is secreted.
- the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- the cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- the recombinant protein product comprises bikunin, Factor VIII, IL2SA, or fragment thereof.
- the chaperone protein comprises calnexin, calreticulin, Erp57, Hsp40, or Hsp70.
- the chaperone protein comprises calreticulin and Erp57.
- the present invention relates to a method and reagents therefor, for enhanced expression of a secreted recombinant protein product in a mammalian host cell.
- a mammalian CHO host cell for enhanced expression of a recombinant bikunin protein comprises genetic material coding for expression of said recombinant bikunin protein and transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- the mammalian host cell is stably transformed with the genetic material coding for expression of said recombinant protein product.
- mammalian host cell is used to refer to a mammalian cell which has been transfected, or is capable of being transfected with a nucleic acid sequence and then of-expressing a selected gene of interest.
- the term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so long as the selected gene is present.
- Suitable mammalian cells for use in the present invention include, but are not limited to Chinese hamster ovary (CHO) cells, and baby hamster kidney (BHK) cells.
- the cell lines are readily available from the ATCC.
- transfection is used to refer to the uptake of foreign or exogenous DNA by a cell, and a cell has been "transfected" when the exogenous DNA has been introduced inside the cell membrane.
- transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham et al., 1973, Virology 52:456 ; Sambrook et al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratories, 1989 ); Davis et al., Basic Methods in Molecular Biology (Elsevier, 1986 ); and Chu et al., 1981, Gene 13:197 .
- Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.
- Suitable techniques of transfection for use in the present invention include, but are not limited to calcium phosphate-mediated transfection, DEAE-dextran mediated transfection, and electroporation.
- Cationic lipid transfection using commercially available reagents including the Boehringer Mannheim Transfection Reagent (N->1-(2,3-Dioleoyloxy)propyl-N,N,N-trimethyl ammoniummethylsulfate, Boehringer Mannheim, Indianapolis, Ind.) or LIPOFECTIN or LIPOFECTAMIN or DMRIE reagent (GIBCO-BRL, Gaithersburg, MD) may also be used.
- the term "super transfection” refers to transfecting more than one expression vectors to a host cell already expressing a recombinant gene.
- transformation refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA.
- a cell is transformed where it is genetically modified from its native state.
- the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid.
- a cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.
- modified cell line refers to a cell line either transiently or stably transformed with one or more DNA constructs.
- Polynucleotides, genetic material, recombinant DNA molecules, expression vectors, and such, used in the practice of the present invention may be isolated using standard cloning methods such as those described by Sambrook et al. (Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., 1989 ).
- the polynucleotides coding for a recombinant protein product of the present invention may be synthesized using standard techniques that are well known in the art, such as by synthesis on an automated DNA synthesizer. For example, DNA sequences encoding the calnexin protein are synthesized by RT-PCR using primers depicted in Figure 1 .
- an "expression vector” refers to a DNA molecule, or a clone of such a molecule, which has been modified through human intervention to contain segments of DNA combined and juxtaposed in a manner that would not otherwise exist in nature.
- DNA constructs may be engineered to include a first DNA segment encoding a polypeptide of the present invention operably linked to additional DNA segments required for the expression of the first DNA segment.
- additional DNA segments will generally include promoters and transcription terminators and may further include enhancers and other elements.
- One or more selectable markers may also be included.
- DNA constructs useful for expressing cloned DNA segments in a variety of prokaryotic and eukaryotic host cells can be prepared from readily available components or purchased from commercial suppliers.
- DNA constructs may also contain DNA segments necessary to direct the secretion of a polypeptide or protein of interest. Such DNA segments may include at least one secretory signal sequence.
- Secretory signal sequences also called leader sequences, prepro sequences and/or pre sequences, are amino acid sequences that act to direct the secretion of mature polypeptides or proteins from a cell. Such sequences are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly synthesized proteins. Very often the secretory peptide is cleaved from the mature protein during secretion. Such secretory peptides contain processing sites that allow cleavage of the secretory peptide from the mature protein as it passes through the secretory pathway.
- a recombinant protein may contain a secretory signal sequence in its original amino acid sequence, or may be engineered to become a secreted protein by inserting an engineered secretory signal sequence into its original amino acid sequence.
- suitable promoters, terminators and secretory signals is well within the level of ordinary skill in the art. Expression of cloned genes in cultured mammalian cells and in E. coli, for example, is discussed in detail in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., 1989 ).
- recombinant protein product refers to a recombinant protein or fragment thereof expressed from the genetic material introduced into the host mammalian cell.
- the cell may be maintained either transiently transformed or stably transformed with said DNA construct.
- Introduction of multiple DNA constructs, and selection of cells containing the multiple DNA constructs can be done either simultaneously or, more preferably, sequentially.
- the technique of establishing a cell line stably transformed with a genetic material or expression vector is well known in the art (Current Protocols in Molecular Biology).
- the growth medium will select for cells containing the DNA construct by, for example, drug selection or deficiency in an essential nutrient, which is complemented by a selectable marker on the DNA construct or co-transfected with the DNA construct.
- Cultured mammalian cells are generally cultured in commercially available serum-containing or serum-free medium. Selection of a medium appropriate for the particular host cell used is within the level of ordinary skill in the art.
- Suitable selectable markers for drug selection used in this invention include, but are not limited to, neomycin (G418), hygromycin, puromycin, zeocin, colchine, methotrexate, and methionine sulfoximine.
- individual clones may be selected and screened for high expressing clones.
- Methods of establishing cloned cell line are well known in the art, including, but not limited to, using a cloning cylinder, or by limiting dilution.
- Expression of the recombinant product of interest from each clone can be measured by methods such as, but not limited to, immunoassay, enzymatic assay, or chromogenic assay.
- Cell line stably transformed with a first DNA construct may be then used as host cell for transfection with a second or more DNA constructs, and subjected to different drug selections.
- a mammalian CHO host cell for enhanced expression of bikunin protein is provided, wherein the mammalian CHO host cell is further transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- bikunin refers to any protein, which has at least one Kunitz domain. Kunitz-type domains have been described in references such as Laskowski et al., 1980, Ann Rev Biochem. 49:593-626 ; and U.S. Patent No. 5,914,315 (June 22, 1999 ).
- the term bikunin used herein refers to the amino acid sequence shown in Figure 5 . Other bikunin proteins and fragments thereof are described in U.S.
- the invention provides a mammalian BHK host cell with enhanced expression and secretion of Factor VIII protein and the mammalian BKH host cell is further transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57 and at least one expression vector comprising calreticulin.
- the Factor VIII protein has the sequence depicted in U.S. Patent No. 4,965,199 .
- a mammalian host cell with enhanced expression and secretion of IL2SA protein or fragment thereof, and the mammalian host cell is further transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.
- a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.
- the IL2SA protein has the sequence depicted in US patent No. 6,348,192 .
- the mammalian host cell with enhanced expression and secretion of IL2SA is a CHO cell.
- the mammalian host cell is further transformed with an expression vector encoding a glutamine synthetase protein.
- the present invention also provides a method for producing a mammalian host cell as defined in claim 1 or 2 for enhanced expression of said target recombinant protein comprising: providing a mammalian cell having genetic material coding for expression of said target recombinant protein; and transforming the mammalian cell with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- the recombinant protein product is bikunin and the transformation occurs with an expression vector comprising DNA encoding Erp57.
- the recombinant protein product is Factor VIII and the transformation occurs with a first expression vector comprising DNA encoding calreticulin and a second expression vector comprising DNA encoding Erp57.
- a recombinant protein product which is Factor VIII or fragment thereof and the transformation occurs with an expression vector comprising DNA encoding calnexin or Hsp70.
- a recombinant protein product which is IL2SA or fragment thereof and the transformation occurs with an expression vector comprising DNA encoding Hsp70.
- the present invention also provides a method for producing a secreted recombinant protein product comprising culturing a mammalian host cell of claim 1 or claim 2, and recovering from the culture medium the recombinant protein so produced and secreted.
- the method for producing a secreted recombinant protein product comprising culturing a mammalian host cell, wherein the mammalian host cell is stably transformed with a genetic material coding for the expression of said recombinant product.
- the method for producing a secreted recombinant protein product further comprises transfecting the mammalian host cell with an expression vector encoding a glutamine synthetase protein.
- One embodiment of the invention provides a method of producing a bikunin protein, comprising culturing a mammalian CHO host cell expressing bikunin, and at least one chaperone protein Erp57; and recovering from the culture medium the bikunin protein so produced and secreted.
- a method for enhanced production of a recombinant bikunin protein in a CHO cell wherein a genetic material coding for expression of said recombinant bikunin has been previously introduced into a first CHO cell line (as described in U.S. Patent Application Serial No. 09/441,654 to Chan filed November 12, 1999 ), comprising the steps of: inserting at least one chaperone protein expression vector comprising DNA encoding Erp57 chaperone protein into said first CHO cell line so as to form a modified CHO cell line; and selecting from said modified CHO cell line at least one second cell exhibiting enhanced yield of the recombinant bikunin protein.
- the method for enhancing recombinant bikunin yield in a CHO cell line comprises introducing a genetic material for such bikunin into a CHO cell line, wherein the CHO cell line exhibits enhanced chaperone protein expression.
- a method for enhanced production of a recombinant Factor VIII protein in a BHK cell comprising the steps of: inserting at least one chaperone protein expression vector comprising DNA encoding Erp57 chaperone protein and DNA encoding CRT chaperone protein into said first BHK cell line so as to form a modified BHK cell line; and selecting from said modified BHK cell line at least one second cell exhibiting enhanced yield of the recombinant Factor VIII protein.
- the method for enhancing recombinant Factor VIII yield in a BHK cell line comprises introducing a genetic material for such Factor VIII into a BHK cell line, wherein the BHK cell line exhibits enhanced chaperone protein expression.
- Also disclosed herein is a method for enhanced production of a recombinant IL2SA protein into a CHO cell, wherein a genetic material coding for expression of said recombinant IL2SA has been previously introduced into a first CHO cell line, comprising the steps of: inserting at least one chaperone protein expression vector into said first CHO cell line so as to form a modified CHO cell line; and selecting from said modified CHO cell line at least one second cell exhibiting enhanced yield of the recombinant IL2SA protein.
- the method for enhancing recombinant IL2SA yield in a CHO cell line comprises introducing a genetic material for such IL2SA into a CHO cell line, wherein the CHO cell line exhibits enhanced chaperone protein expression.
- the PCR reactions were performed using high fidelity PFU enzyme (Stratagene). Bands of the expected size were purified, digested with EcoR I and Xba I and cloned into the similarly digested pCI-neo vector. Recombinant vectors from this step were propagated in E. Coli followed by isolation and purification of the vector sequences.
- the sequence inserts representing the chaperones were sequenced using primers binding just outside the multiple cloning sites of the vector as well as within the chaperone sequence. Sequencing was done using the Big Dye terminator method on MJ Research's thermal cycler and analyzed using an ABI 310 Genetic Analyzer. The cDNA sequences of human calnexin, clareticulin and Erp57 are shown in Figures 2A-2C .
- the primer sequences of Hsp 70 were derived from the previously published sequence for the human heat shock protein (Hsp70) gene [9].
- the F-Hsp70 and R-Hsp70 primers included either an EcoRI or XbaI sequence respectively.
- the desired PCR fragment was purified by agarose gel electrophoresis and confirmed by nucleotide sequencing.
- the full-length human Hsp70 cDNA fragment was then inserted into the EcoRI and XbaI cloning sites of the pCI-neo vector to form the pCI-neo-Hsp70 vector.
- the pCI-neo-Hsp70 vector was propagated in E. Coli followed by isolation and purification of the vector sequences.
- pCI-neo-Hsp70 plasmid DNA was sequenced by ABI PRISM 310 Genetic Analyzer. The sequence of human Hsp70 is shown in Figure 2D .
- Bikunin production is increased in CHO cells after transfection of an ER chaperone such as calnexin, calreticulin, Erp57 or Hsp70.
- an ER chaperone such as calnexin, calreticulin, Erp57 or Hsp70.
- a CHO cell line secreting the Bikunin recombinant protein ( U.S. Patent Application Serial No. 09/441654 ) was super transfected with various combinations of the ER chaperones, calnexin (CNX), calreticulin (CRT), ERp57 or Hsp70 followed by selection with G418. Populations were obtained and screened by kallikrein assay ( U.S. Patent Application Serial No. 09/441,654 ). Briefly, bikunin standarts or culture fluid was serially diluted and incubated with an equal volume of kallikrein at 37°C for 30 minutes, after which a chromogenic substrate, N-benzoyl-Pro-Phe-Arg-pNA, was added.
- the specific Bikunin production rate for all cell lines is expressed as pg Bikunin/cell/day (SPR).
- SPR specific Bikunin production rate for all cell lines.
- SPR pg Bikunin/cell/day
- cells were harvested and transferred into fresh media and incubated for 24 hours at 37°C in shaking flasks. The following day, cells were harvested again, counted and re-suspended into fresh media of the same volume and incubated similarly for another 24 hours.
- Bikunin activity measurements (pg/cell/day) were conducted on samples of the spent media. The same procedure was repeated every day until the cell number and viability started to decrease.
- Example 3 Recombinant Factor VIII production is increased in BHK cells after transfection with ER chaperones.
- MWCB1 Stable Factor VIII producing cells
- pPUR a vector containing puromycin-resistant gene
- Approximately 4 x 10 6 MWCB1 cells were transfected with a total of 5 ⁇ g of DNA using the DMRIE-C reagent and OPTI-MEM medium (Life Technology, MD) in 6-well plates.
- OPTI-MEM medium Life Technology, MD
- Recombinant CHO cells (as described in Example 2) expressing high levels of bikunin, and recombinant BHK cells (as described in Example 3) expressing high levels of recombinant Factor VIII (rFVIII) were super-transfected with pHyg (plasmid conferring hygromycin resistance) and pBiP.
- the transfection conditions and selection conditions were same as in Example 2.
- clones were evaluated for productivity for bikunin and rFVIII activity. No significant difference in the specific productivity of clones derived from cells transfected only with the control vector (pHyg) and clones derived from cells transfected with pBiP.
- IL2SA IL2 selective agonist
- U.S. Patent No. 6,348,192 producing CHO cell line, 49-19-H42 (a clonal variant of ATCC deposit PTA-8) was co-transfected with PCI-GS and PCI-neo-Hsp70.
- 4 x 10 6 cells were transfected with 2.5 ⁇ g of plasmid DNA using DMRIE-C reagents and OPTI-MEM medium (Life Technology, MD) in 6-well plates according to manufacturer's instructions.
- GS and Hsp70 proteins were confirmed by FACS analysis using a flow cytometer.
- the "GS positive" cells were cultured in a glutamine-free medium supplement with 5.6 mM glutamate and 4 g/L glucose. The doubling time of these clones varied from 24 to 48 hr.
- a comparison of the productivity of the parent and clones is shown in Table 3.
- a 2- 4 fold increase in overall titer and a 2 -3 fold increase in specific productivity was observed in all the single cell clones when compared against either the pool or the parental line. Table 3.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Description
- The present invention relates to the general field of recombinant protein production in a mammalian host cell. Specifically, the present invention relates to enhanced production of a recombinant bikunin or Factor VIII protein by coexpressing at least one Erp57 chaperone protein in the mammalian host cell.
- In both procaryotic and eucaryotic cells, molecular chaperone proteins catalyze disulfide bond exchange and assist in the proper folding of newly synthesized proteins. This observation has led to a large number of studies and proposed uses for these quality control proteins. For example, increasing pDI (protein disulfide isomerase) activity in bacterial, yeast and insect cell expression systems can have beneficial effects on protein solubility and folding and, in some cases, can lead to an increase in the secretion of heterologous proteins (1-7). In addition, other studies have shown that the molecular chaperones immunoglobulin heavy chain binding protein (BiP, also referred to as glucose regulated protein) and human heat shock protein 70 (Hsp 70) have a beneficial effect on recombinant protein expression in insect cell systems (5, 8-12).
- Molecular chaperones have not had the same level of success on recombinant protein expression and secretion in mammalian cell systems. For example, overexpression of the pDI chaperone in Chinese hamster ovary (CHO) cells not only had no effect on the secretion levels of IL-15, but also caused a decrease in secretion, and an increase in cellular retention of a tumor necrosis factor receptor-Fc fusion protein (TNFR:Fc) (13). Other studies have shown that overexpression of the BiP chaperone in mammalian cells can lead to increased cellular retention and decreased secretion of recombinant proteins (14-15 and
U.S. Patent No. 4,912,040 ). The regulatory mechanisms involved in protein processing within the mammalian cell are complex, and probably involve the cooperation of many of these chaperone proteins. Therefore, one cannot predict whether a particular chaperone will lead to an increase in the production of a certain recombinant protein. - Because of the contradictory teaching in the field, the effect of chaperone proteins on the production of a secreted recombinant protein product is not understood and appreciated.
U.S. Patent No. 6,451,597 (the '597 patent) describes a method for enhanced production of viral particles, and speculates on the effect of chaperones on improving yield of a recombinant protein in eukaryotic cells. However, no actual expression of a recombinant protein is disclosed. However, other studies had found that over-expression of chaperones in eukaryotic cell lines either had no effect on product yields or had reduced secretion of recombinant proteins (14, 15). See alsoU.S. Patent No. 4,912,040 . In light of the contradictory teaching in the field, the '597 patent does not enable one of skill in the art to use chaperones to improve the production and secretion of a recombinant protein in eukaryotic cells. The state of art does not teach one to predict what effect a particular chaperone will have in the production and secretion of a given recombinant protein in cell culture models such as those described herein. The applicants were therefore surprised to find that when the chaperones described in this study were transfected into mammalian cell lines expressing a secreted, recombinant protein, the resultant effect was an overall increase in the production of the secreted protein. - In a first aspect of the invention, a mammalian CHO host cell for enhanced expression of a recombinant bikunin protein is provided, said mammalian CHO cell having genetic material coding for expression of said recombinant bikunin protein and transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- In one embodiment of the first aspect of the invention, the recombinant protein product is secreted.
- In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- In another aspect of the invention, a method for producing a mammalian CHO host cell for enhanced expression of a recombinant bikunin protein is provided, wherein the method comprises providing a mammalian CHO cell having genetic material coding for expression of recombinant bikunin protein; and transforming the mammalian CHO cell with at least one expression vector comprising DNA encoding a chaperone protein Erp57.
- In one embodiment of this aspect of the invention, the recombinant protein product is secreted.
- In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- In another aspect of the invention, a method for producing a secreted recombinant protein product is provided, the method comprising the steps of: culturing a mammalian host cell of
claim 1 orclaim 2, and recovering from the culture medium the recombinant protein so produced and secreted. - In one embodiment of this aspect of the invention, the recombinant protein product is secreted.
- In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- In another aspect of the invention, a method for enhancing yield of a recombinant bikunin protein is provided, wherein genetic material coding for expression of said recombinant protein has been previously introduced into the cell line to form the first cell line, said method comprising the steps of: inserting at least one chaperone protein expression vector comprising DNA incoding Erp57 chaperone protein into said first cell line so as to form a modified cell line; and selecting from said modified cell line at least one second cell line exhibiting enhanced yield of the recombinant protein.
- In one embodiment of this aspect of the invention, the recombinant protein product is secreted.
- In another embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into the first cell line DNA.
- In another embodiment of the invention, the second cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- In another embodiment of the invention, at least one second cell line is produced from said first cell line by selecting a portion of said first cell line exhibiting integration of the chaperone protein expression vector into host DNA.
- Also disclosed is a method for enhancing yield of a recombinant protein or fragment thereof in a mammalian cell, the method comprises introducing genetic material coding for a recombinant protein or fragment thereof into a cell line exhibiting enhanced chaperone protein expression.
- In one embodiment the recombinant protein product is secreted.
- In another embodiment, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- In another embodiment, the cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- In another embodiment, the recombinant protein product comprises bikunin, Factor VIII, IL2SA, or fragment thereof.
- In another embodiment, the chaperone protein comprises calnexin, calreticulin, Erp57, Hsp40, or Hsp70.
- In another embodiment, the chaperone protein comprises calreticulin and Erp57.
- The invention will be better understood from a consideration of the following detailed description and claims, taken in conjunction with the drawings, in which:
-
Figure 1 depicts the sequences of RT-PCR primers used to amplify cDNA of ER chaperones from a human cDNA library. Underlined indicates a built in EcoRI (5' primer) or XbaI (3' primer) restriction site. CNX: calnexin; CRT: calreticulin; -
Figure 2A depicts the complete nucleotide and amino acid sequences of calnexin cloned by RT-PCR. The 5' EcoRI and 3' XbaI sites within the primers are underlined. The start codon and stop codon are shown in bold text; -
Figure 2B depicts the complete nucleotide and amino acid sequences of calreticulin cloned by RT-PCR. The 5' EcoRI and 3' XbaI sites are underlined. The start codon and stop codon are shown in bold text; -
Figure 2C depicts the complete nucleotide and amino acid sequences of Erp57 cloned by RT-PCR. The 5' EcoRI and 3' XbaI sites are underlined. The start codon and stop codon are shown in bold text; -
Figure 2D depicts the complete nucleotide and amino acid sequences of the coding region of the human Hsp70 gene; -
Figure 2E depicts the complete nucleotide and amino acid sequences of the coding region of the human Hsp40 gene. The start codon is shown in bold and underlined text; -
Figure 2F depicts the complete nucleotide and amino acid sequences of the coding region of the glutamine synthetase gene. The start codon is shown in bold and underlined text; -
Figure 3 is an illustration of overexpression of bikunin in clones super transfected with calnexin (X4.14:5, X4/14:30), Hsp70 (7-3) or Erp57(X4/19:62). The specific Bikunin production rate for all cell lines is expressed as pg Bikunin/cell/day (SPR). Each day cells were harvested and transferred into fresh media and incubated for 24 hours at 37°C in shaking flasks. The following day, cells were harvested again, counted and re-suspended into fresh media of the same volume and incubated similarly for another 24 hours. Bikunin activity measurements (pg/cell/day) were conducted on samples of the spent media. The same procedure was repeated every day until the cell number and viability started to decrease. The control cell line (CF 9-20) expresses bikunin but does not express any of chaperone proteins; -
Figure 4 is an illustration of overexpression of bikunin in clones super transfected with Hsp70. All clones except CF9-20 (control cells) are super transfected with Hsp70. The experiment procedure is the same as that described inFigure 3 ; and -
Figure 5 depicts the amino acid sequence of bikunin. - The present invention relates to a method and reagents therefor, for enhanced expression of a secreted recombinant protein product in a mammalian host cell.
- In one embodiment of the invention, a mammalian CHO host cell for enhanced expression of a recombinant bikunin protein is provided, wherein said mammalian CHO cell comprises genetic material coding for expression of said recombinant bikunin protein and transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- In another embodiment of the invention, the mammalian host cell is stably transformed with the genetic material coding for expression of said recombinant protein product.
- The term "mammalian host cell" is used to refer to a mammalian cell which has been transfected, or is capable of being transfected with a nucleic acid sequence and then of-expressing a selected gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so long as the selected gene is present.
- Suitable mammalian cells for use in the present invention include, but are not limited to Chinese hamster ovary (CHO) cells, and baby hamster kidney (BHK) cells. The cell lines are readily available from the ATCC.
- The term "transfection" is used to refer to the uptake of foreign or exogenous DNA by a cell, and a cell has been "transfected" when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham et al., 1973, Virology 52:456; Sambrook et al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratories, 1989); Davis et al., Basic Methods in Molecular Biology (Elsevier, 1986); and Chu et al., 1981, Gene 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.
- Suitable techniques of transfection for use in the present invention include, but are not limited to calcium phosphate-mediated transfection, DEAE-dextran mediated transfection, and electroporation. Cationic lipid transfection using commercially available reagents including the Boehringer Mannheim Transfection Reagent (N->1-(2,3-Dioleoyloxy)propyl-N,N,N-trimethyl ammoniummethylsulfate, Boehringer Mannheim, Indianapolis, Ind.) or LIPOFECTIN or LIPOFECTAMIN or DMRIE reagent (GIBCO-BRL, Gaithersburg, MD) may also be used.
- As used herein the term "super transfection" refers to transfecting more than one expression vectors to a host cell already expressing a recombinant gene.
- The term "transformation" as used herein refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transfection, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.
- As used herein the term "modified cell line" refers to a cell line either transiently or stably transformed with one or more DNA constructs.
- Polynucleotides, genetic material, recombinant DNA molecules, expression vectors, and such, used in the practice of the present invention may be isolated using standard cloning methods such as those described by Sambrook et al. (Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., 1989). Alternatively, the polynucleotides coding for a recombinant protein product of the present invention may be synthesized using standard techniques that are well known in the art, such as by synthesis on an automated DNA synthesizer. For example, DNA sequences encoding the calnexin protein are synthesized by RT-PCR using primers depicted in
Figure 1 . - As used herein an "expression vector" refers to a DNA molecule, or a clone of such a molecule, which has been modified through human intervention to contain segments of DNA combined and juxtaposed in a manner that would not otherwise exist in nature. DNA constructs may be engineered to include a first DNA segment encoding a polypeptide of the present invention operably linked to additional DNA segments required for the expression of the first DNA segment. Within the context of the present invention additional DNA segments will generally include promoters and transcription terminators and may further include enhancers and other elements. One or more selectable markers may also be included. DNA constructs useful for expressing cloned DNA segments in a variety of prokaryotic and eukaryotic host cells can be prepared from readily available components or purchased from commercial suppliers.
- DNA constructs may also contain DNA segments necessary to direct the secretion of a polypeptide or protein of interest. Such DNA segments may include at least one secretory signal sequence. Secretory signal sequences, also called leader sequences, prepro sequences and/or pre sequences, are amino acid sequences that act to direct the secretion of mature polypeptides or proteins from a cell. Such sequences are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly synthesized proteins. Very often the secretory peptide is cleaved from the mature protein during secretion. Such secretory peptides contain processing sites that allow cleavage of the secretory peptide from the mature protein as it passes through the secretory pathway. A recombinant protein may contain a secretory signal sequence in its original amino acid sequence, or may be engineered to become a secreted protein by inserting an engineered secretory signal sequence into its original amino acid sequence. The choice of suitable promoters, terminators and secretory signals is well within the level of ordinary skill in the art. Expression of cloned genes in cultured mammalian cells and in E. coli, for example, is discussed in detail in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., 1989).
- As used herein, the term "recombinant protein product" refers to a recombinant protein or fragment thereof expressed from the genetic material introduced into the host mammalian cell.
- After transfection, the cell may be maintained either transiently transformed or stably transformed with said DNA construct. Introduction of multiple DNA constructs, and selection of cells containing the multiple DNA constructs can be done either simultaneously or, more preferably, sequentially. The technique of establishing a cell line stably transformed with a genetic material or expression vector is well known in the art (Current Protocols in Molecular Biology). In general, after transfection, the growth medium will select for cells containing the DNA construct by, for example, drug selection or deficiency in an essential nutrient, which is complemented by a selectable marker on the DNA construct or co-transfected with the DNA construct. Cultured mammalian cells are generally cultured in commercially available serum-containing or serum-free medium. Selection of a medium appropriate for the particular host cell used is within the level of ordinary skill in the art.
- Suitable selectable markers for drug selection used in this invention include, but are not limited to, neomycin (G418), hygromycin, puromycin, zeocin, colchine, methotrexate, and methionine sulfoximine.
- Once a drug resistant cell population is established, individual clones may be selected and screened for high expressing clones. Methods of establishing cloned cell line are well known in the art, including, but not limited to, using a cloning cylinder, or by limiting dilution. Expression of the recombinant product of interest from each clone can be measured by methods such as, but not limited to, immunoassay, enzymatic assay, or chromogenic assay.
- Cell line stably transformed with a first DNA construct may be then used as host cell for transfection with a second or more DNA constructs, and subjected to different drug selections.
- In one embodiment of the invention, a mammalian CHO host cell for enhanced expression of bikunin protein is provided, wherein the mammalian CHO host cell is further transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- As used herein the term "bikunin" refers to any protein, which has at least one Kunitz domain. Kunitz-type domains have been described in references such as Laskowski et al., 1980, Ann Rev Biochem. 49:593-626; and
U.S. Patent No. 5,914,315 (June 22, 1999 ). In one preferred embodiment, the term bikunin used herein refers to the amino acid sequence shown inFigure 5 . Other bikunin proteins and fragments thereof are described inU.S. Application serial numbers 09/144,428 ,09/974,026 09/218,913 09/441,966 PCT Application serial numbers US97/03894 WO 97/33996 US99/04381 WO 00/37099 - In another embodiment of the invention, the invention provides a mammalian BHK host cell with enhanced expression and secretion of Factor VIII protein and the mammalian BKH host cell is further transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57 and at least one expression vector comprising calreticulin.
- In one preferred embodiment, the Factor VIII protein has the sequence depicted in
U.S. Patent No. 4,965,199 . - Also disclosed herein is a mammalian host cell with enhanced expression and secretion of IL2SA protein or fragment thereof, and the mammalian host cell is further transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.
- In one preferred embodiment, the IL2SA protein has the sequence depicted in
US patent No. 6,348,192 . - In yet another preferred embodiment, the mammalian host cell with enhanced expression and secretion of IL2SA is a CHO cell.
- In still another embodiment of the invention, the mammalian host cell is further transformed with an expression vector encoding a glutamine synthetase protein.
- The present invention also provides a method for producing a mammalian host cell as defined in
claim - In one embodiment of the invention, the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- In another embodiment of the invention, the mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- In one preferred embodiment of the invention, the recombinant protein product is bikunin and the transformation occurs with an expression vector comprising DNA encoding Erp57.
- In another preferred embodiment of the invention, the recombinant protein product is Factor VIII and the transformation occurs with a first expression vector comprising DNA encoding calreticulin and a second expression vector comprising DNA encoding Erp57.
- Also disclosed herein is a recombinant protein product which is Factor VIII or fragment thereof and the transformation occurs with an expression vector comprising DNA encoding calnexin or Hsp70.
- Also disclosed herein is a recombinant protein product which is IL2SA or fragment thereof and the transformation occurs with an expression vector comprising DNA encoding Hsp70.
- The present invention also provides a method for producing a secreted recombinant protein product comprising culturing a mammalian host cell of
claim 1 orclaim 2, and recovering from the culture medium the recombinant protein so produced and secreted. - In one embodiment of the invention, the method for producing a secreted recombinant protein product comprising culturing a mammalian host cell, wherein the mammalian host cell is stably transformed with a genetic material coding for the expression of said recombinant product.
- In another embodiment of the invention, the method for producing a secreted recombinant protein product further comprises transfecting the mammalian host cell with an expression vector encoding a glutamine synthetase protein.
- One embodiment of the invention provides a method of producing a bikunin protein, comprising culturing a mammalian CHO host cell expressing bikunin, and at least one chaperone protein Erp57; and recovering from the culture medium the bikunin protein so produced and secreted.
- In one embodiment of the invention, a method for enhanced production of a recombinant bikunin protein in a CHO cell is provided, wherein a genetic material coding for expression of said recombinant bikunin has been previously introduced into a first CHO cell line (as described in
U.S. Patent Application Serial No. 09/441,654 to Chan filed November 12, 1999 - In another embodiment, the method for enhancing recombinant bikunin yield in a CHO cell line comprises introducing a genetic material for such bikunin into a CHO cell line, wherein the CHO cell line exhibits enhanced chaperone protein expression.
- In yet another embodiment of the invention, a method for enhanced production of a recombinant Factor VIII protein in a BHK cell is provided, wherein a genetic material coding for expression of said recombinant Factor VIII has been previously introduced into a first BHK cell line, comprising the steps of: inserting at least one chaperone protein expression vector comprising DNA encoding Erp57 chaperone protein and DNA encoding CRT chaperone protein into said first BHK cell line so as to form a modified BHK cell line; and selecting from said modified BHK cell line at least one second cell exhibiting enhanced yield of the recombinant Factor VIII protein.
- In still another embodiment, the method for enhancing recombinant Factor VIII yield in a BHK cell line comprises introducing a genetic material for such Factor VIII into a BHK cell line, wherein the BHK cell line exhibits enhanced chaperone protein expression.
- Also disclosed herein is a method for enhanced production of a recombinant IL2SA protein into a CHO cell, wherein a genetic material coding for expression of said recombinant IL2SA has been previously introduced into a first CHO cell line, comprising the steps of: inserting at least one chaperone protein expression vector into said first CHO cell line so as to form a modified CHO cell line; and selecting from said modified CHO cell line at least one second cell exhibiting enhanced yield of the recombinant IL2SA protein.
- In another embodiment, the method for enhancing recombinant IL2SA yield in a CHO cell line comprises introducing a genetic material for such IL2SA into a CHO cell line, wherein the CHO cell line exhibits enhanced chaperone protein expression.
- The following examples are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.
- All chaperone sequences were cloned from human cDNA libraries followed by verification of the nucleotide sequences. DNA sequences representing the three ER chaperones were cloned by RT-PCR from a human cDNA library. The RT-PCR primers used in these reactions were designed to amplify the entire coding region using the appropriate sequences obtained from Genbank. Each pair of 5' and 3' primers include either an EcoRI (5' primer) or XbaI (3' primer) restriction site (
Figure 1 ) to facilitate cloning of the PCR product into the expression vector, pCI-neo (Promega). - The PCR reactions were performed using high fidelity PFU enzyme (Stratagene). Bands of the expected size were purified, digested with EcoR I and Xba I and cloned into the similarly digested pCI-neo vector. Recombinant vectors from this step were propagated in E. Coli followed by isolation and purification of the vector sequences. The sequence inserts representing the chaperones were sequenced using primers binding just outside the multiple cloning sites of the vector as well as within the chaperone sequence. Sequencing was done using the Big Dye terminator method on MJ Research's thermal cycler and analyzed using an ABI 310 Genetic Analyzer. The cDNA sequences of human calnexin, clareticulin and Erp57 are shown in
Figures 2A-2C . - The full-length human Hsp70 cDNA fragment was obtained by RT-PCR using human brain polyA+ RNA (CLONTECH Cat: 6516-1) and two primers designated F-Hsp70 = 5' AGG GAA CCG CAT GGC CAA AG and R-Hsp70 = 5' GAA AGG CCCCTA ATC TAC CTC CTC A. The primer sequences of Hsp 70 were derived from the previously published sequence for the human heat shock protein (Hsp70) gene [9]. The F-Hsp70 and R-Hsp70 primers included either an EcoRI or XbaI sequence respectively. The desired PCR fragment was purified by agarose gel electrophoresis and confirmed by nucleotide sequencing. The full-length human Hsp70 cDNA fragment was then inserted into the EcoRI and XbaI cloning sites of the pCI-neo vector to form the pCI-neo-Hsp70 vector. The pCI-neo-Hsp70 vector was propagated in E. Coli followed by isolation and purification of the vector sequences. pCI-neo-Hsp70 plasmid DNA was sequenced by ABI PRISM 310 Genetic Analyzer. The sequence of human Hsp70 is shown in
Figure 2D . - A CHO cell line secreting the Bikunin recombinant protein (
U.S. Patent Application Serial No. 09/441654 ) was super transfected with various combinations of the ER chaperones, calnexin (CNX), calreticulin (CRT), ERp57 or Hsp70 followed by selection with G418. Populations were obtained and screened by kallikrein assay (U.S. Patent Application Serial No. 09/441,654 ). Briefly, bikunin standarts or culture fluid was serially diluted and incubated with an equal volume of kallikrein at 37°C for 30 minutes, after which a chromogenic substrate, N-benzoyl-Pro-Phe-Arg-pNA, was added. The reaction was incubated for 15 minutes before the addition of 50% acetic acid. The amount of p-nitroanilide released was measured at 405 nM. Populations showing the highest Bikunin titers were then single cell cloned and growth expanded over a period of several weeks. Clones showing consistently higher Bikunin titers (2-4x) relative to the control CF9-20 cells were retained and expanded into shake flasks for further analysis. These clones were further narrowed based on Bikunin titers and growth characteristics demonstrated while growing in the shake flask environment. Final candidate clones were selected after several rounds and extensive analyses at the shake flask stage. - The specific Bikunin production rate for all cell lines is expressed as pg Bikunin/cell/day (SPR). Each day cells were harvested and transferred into fresh media and incubated for 24 hours at 37°C in shaking flasks. The following day, cells were harvested again, counted and re-suspended into fresh media of the same volume and incubated similarly for another 24 hours. Bikunin activity measurements (pg/cell/day) were conducted on samples of the spent media. The same procedure was repeated every day until the cell number and viability started to decrease.
- The effect of chaperone proteins on bikunin expression is shown in
Figures 3 and4 . The control cell line (CF9-20) expresses Bikunin but does not express any of chaperone proteins. The effect of calnexin, calreticulin, and Erp57 on bikunin expression is further summarized in Table 1.Table 1. Overall Bikunin production levels are 2-4 fold higher in clones that have been super transfected with a chaperone Clone Bikunin Increase Relative to Control Chaperone X4/14:5 2-4 CNX X4/14:30 2-4 CNX X4/19:62 2-4 ERp57 T4/13:22 1.5-2 CRT - Stable Factor VIII producing cells (MWCB1) (
U.S. Patent No. 4,965,199 ; ATCC No. CRL 8544) were transfected with chaperone expression vectors in addition to pPUR, a vector containing puromycin-resistant gene, in a 10 : 1 ratio. Approximately 4 x 106 MWCB1 cells were transfected with a total of 5 µg of DNA using the DMRIE-C reagent and OPTI-MEM medium (Life Technology, MD) in 6-well plates. Three days post transfection, 100,000 cells were seeded in 6-well plates and then selected in the presence of 1 - 2 µg/ ml puromycin with OPTI-MEM medium containing 2% FBS for 2 weeks. Puromycin resistant colonies were manually picked and seeded into 96 well plates and expanded without the presence of drug. Individual clonal populations were screened for Factor VIII production using a COATEST kit (Chromogenix, Italy) according to manufacturer's instructions. The high producing clones were sequentially expanded from the 6 well dish, to T75 flask, followed by shake flask stage for stability and productivity tests. The Calnexin (CNX), Calreticulin (CRT), Erp57, Hsp40 and Hsp70 chaperones were then transfected into cells individually or in combinations of two. A significant 2 to 3 fold increase of productivity of Factor VIII was observed in clones transfected with CNX, CRT and Erp57, Hsp70, and Hsp40 while the empty vector control (PCI-Neo) showed no difference compared to the parent MWCB1 cells (Table 2).Table 2. Recombinant Factor VIII productivity in clones Factor VIII (U/ml) Fold of Inc (SPR) MWCB1(27000JC) 0.11 1.00 PCI-Neo + pPUR 0.09 1.00 CNX + pPUR 0.31 2.88 CRT + pPUR 0.13 1.25 Erp57 + pPUR 0.05 0.91 CRT, Erp57 + pPUR 0.29 2.50 Hsp70 + pPUR 0.37 2.50 Hsp40 + pPUR 0.11 1.00 Hsp70, 40 + pPUR 0.28 1.66 - Recombinant CHO cells (as described in Example 2) expressing high levels of bikunin, and recombinant BHK cells (as described in Example 3) expressing high levels of recombinant Factor VIII (rFVIII) were super-transfected with pHyg (plasmid conferring hygromycin resistance) and pBiP. The transfection conditions and selection conditions were same as in Example 2. After selection in hygromycin and limiting dilution cloning, clones were evaluated for productivity for bikunin and rFVIII activity. No significant difference in the specific productivity of clones derived from cells transfected only with the control vector (pHyg) and clones derived from cells transfected with pBiP.
- IL2SA (IL2 selective agonist;
U.S. Patent No. 6,348,192 ) producing CHO cell line, 49-19-H42 (a clonal variant of ATCC deposit PTA-8), was co-transfected with PCI-GS and PCI-neo-Hsp70. 4 x 106 cells were transfected with 2.5 µg of plasmid DNA using DMRIE-C reagents and OPTI-MEM medium (Life Technology, MD) in 6-well plates according to manufacturer's instructions. Three days after transfection, cells were seeded in 150-mm and 96 well plates and then selected in the presence of 10 µM MSX (methionine sulfoxinmine) and 250 µg/ml G418 with DME:F12 (1:1) medium deficient in glutamine containing 2% dialyzed FBS for 2 weeks. Single cell colonies were picked and re-seeded in 96 wells. The clones were selected for another week with increased concentrations of MSX (20 µM) and G418 (400 µg/ml). A pool is generated from a 150-mm plate after 3 weeks' selection. The pool and clones were gradually expanded to shake flasks and screened for IL2 productivity using ELISA. The expression of GS and Hsp70 proteins were confirmed by FACS analysis using a flow cytometer. The "GS positive" cells were cultured in a glutamine-free medium supplement with 5.6 mM glutamate and 4 g/L glucose. The doubling time of these clones varied from 24 to 48 hr. A comparison of the productivity of the parent and clones is shown in Table 3. A 2- 4 fold increase in overall titer and a 2 -3 fold increase in specific productivity was observed in all the single cell clones when compared against either the pool or the parental line.Table 3. Productivity of IL2SA producing cells Titer (µg/ml) Cell density (106/ml) SPR (pg/c/d) GS Hsp70 49-19H42 parent line 18.78 3.51 2.67 (-) (-) 49-19H42 GShsp70- SC# 1233.87 2.63 6.44 +++ +++ 49-19H42 GShsp70- SC# 1422.08 1.83 6.03 +++ +++ 49-19H42 GShsp70-SC#17 64.00 3.05 10.50 +++ +++ 49-19H42 GShsp70-pool 10.59 1.74 3.04 +++ + day 0 in 15 ml of complete (for the parental line) or glutamine-free medium. Samples were taken at 2 day after seeding and analyzed using ELISA. For GS and Hsp70 expression, cells were fixed with 70% EtOH, labeled with proper antibodies, and analyzed by FACS. ++ + = all cells expressed GS or Hsp70; + = 30% of cells expressed GS or Hsp70; (-) = no expression. -
- (1) Wunderlich, M.; Glockshuber, R. In vivo control of redox potential during protein folding catalyzed by bacterial protein disulfide-isomerase (DsbA). J. Biol. Chem. 1993, 268, 24547-24550.
- (2) Glockshuber, R.; Wunderlich, M.; Skerra, A.; Rudolph, R. Increasing the yield of disulfide-bridged heterologous proteins secreted from transgenic microorganisms. Eur. Pat. No.
92-106978 920423 1995 - (3) Tuite, M. F.; Freedman, R. B.; Schultz, L. D.; Ellis, R. W.; Markus, H. Z.; Montgomery, D. L. Method for increasing production of disulfide bonded recombinant proteins by saccharomyces cerevisiae. Aust. Pat. No.
AU679448B2 1997 - (4) Ostermeier, M.; De Sutter, K.; Georgiou, G. Eukaryotic protein disulfide isomerase complements Escherichia coli dsbA mutants and increases the yield of a heterologous secreted protein with disulfide bonds. J. Biol. Chem. 1996,271, 10616-10622.
- (5) Shusta, E. V.; Raines, R. T.; Pluckthun, A.; Wittrup, K. D. Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. Nat. Bio-technol. 1998, 16, 773-777.
- (6) Robinson, A. S.; Hines, V.; Wittrup, K. D. Protein disulfide isomerase overexpression increases secretion of foreign proteins in Saccharomyces cerevisiae. Biotechnology (N.Y.) 1994,12, 381-384.
- (7) Dunn, A.; Luz, J. M.; Natalia, D.; Gamble, J. A.; Freedman, R. B.; Tuite, M. F. Protein disulphide isomerase (PDI) is required for the secretion of a native disulphide-bonded protein from Saccharomyces cerevisiae. Biochem. Soc. Trans. 1995, 23, 78S.
- (8) Hsu, T. A.; Watson, S.; Eiden, J. J.; Betenbaugh, M. J. Rescue of immunoglobulins from insolubility is facilitated by PDI in the baculovirus expression system. Protein Expr. Purif. 1996, 7, 281-288.
- (9) Hsu, T. A.; Betenbaugh, M. J. Co-expression of molecular chaperone BiP improves immunoglobulin solubility and IgG secretion from Trichoplusia in insect cells. Biotechnol. Prog. 1997, 13,96-104.
- (10) Hsu, T. A.; Eiden, J. J.; Bourgarel, P.; Meo, T.; Betenbaugh, M. J. Effects of coexpressing chaperone BiP on functional antibody production in the baculovirus system. Protein Expr. Purif. 1994, 5, 595-603.
- (11) Ailor, E.; Betenbaugh, M. J. Overexpression of a cytosolic chaperone to improve solubility and secretion of a recombinant IgG protein in insect cells. Biotechnol. Bioeng. 1998, 58, 196-203.
- (12) Ailor, E.; Betenbaugh, M. J. Modifying secretion and post-translational processing in insect cells. Curr. Opin. Biotechnol. 1999, 10, 142-145.
- (13) Davis, R., Schooley, K., Rasmussen, B., Thomas, J., Reddy, P. Effect of PDI Overexpression on Recombinant Protein Secretion in CHO Cells. Biotechnol. Prog. 2000, 16, 736-743.
- (14) Domer, A. J.; Wasley, L. C.; Raney, P.; Haugejorden, S.; Green, M.; Kaufman, R. J. The stress response in Chinese hamster ovary cells. Regulation of ERp72 and protein disulfide isomerase expression and secretion. J. Biol. Chem. 1990, 265, 22029-22034.
- (15) Domer, A. J.; Wasley, L. C.; Kaufman, R. J. Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO J. 1992,11,1563-1571.
- (16) Current Protocols in Molecular Biology, 2003, John Wiley & Sons, Inc.
- Also disclosed herein are the following:
- 1. A mammalian host cell for enhanced expression of a recombinant protein product, said mammalian cell having genetic material coding for expression of said recombinant protein product and transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.
- 2. The mammalian host cell according to
embodiment 1, wherein the recombinant protein product is secreted. - 3. The mammalian host cell according to
embodiment 2, wherein the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA. - 4. The mammalian host cell according to
embodiment 3, further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein. - 5. The mammalian host cell according to
embodiment 2, wherein the recombinant protein product is bikunin or fragment thereof. - 6. The mammalian host cell according to
embodiment 5, wherein the transformation occurs with an expression vector comprising DNA encoding calnexin. - 7. The mammalian host cell according to
embodiment 5, wherein the transformation occurs with an expression vector comprising DNA encoding Erp57. - 8. The mammalian host cell according to
embodiment 5, wherein the transformation occurs with an expression vector comprising DNA encoding calreticulin. - 9. The mammalian host cell according to
embodiment 5, wherein the transformation occurs with an expression vector comprising DNA encoding Hsp70. - 10. The mammalian host cell according to
embodiment 2 wherein the recombinant protein product is Factor VIII or fragment thereof. - 11. The mammalian host cell according to
embodiment 10 wherein said transformation occurs with a first expression vector comprising DNA encoding calreticulin and a second expression vector comprising DNA encoding Erp57. - 12. The mammalian host cell according to
embodiment 10 wherein said transformation occurs with an expression vector comprising DNA encoding calnexin. - 13. The mammalian host cell according to
embodiment 10, wherein said transformation occurs with an expression vector comprising DNA encoding Hsp70. - 14. The mammalian host cell according to
embodiment 2 wherein the recombinant protein product is IL2SA or fragment thereof. - 15. The mammalian host cell according to
embodiment 14, wherein said transformation occurs with an expression vector comprising DNA encoding Hsp70. - 16. A mammalian host cell for enhanced expression of bikunin or fragment thereof, said mammalian cell having genetic material coding for expression of bikunin or fragment thereof and transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.
- 17. The mammalian host cell according to embodiment 16, wherein the genetic material coding for expression of bikunin or fragment thereof is integrated into the host cell DNA.
- 18. The mammalian host cell according to embodiment 16, further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 19. A mammalian host cell for enhanced expression of Factor VIII or fragment thereof, said mammalian cell having genetic material coding for expression of Factor VIII or fragment thereof and transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, hsp40, and Hsp70.
- 20. The mammalian host cell according to
embodiment 19, wherein the genetic material coding for expression of Factor VIII or fragment thereof is integrated into the host cell DNA. - 21. The mammalian host cell according to embodiment 20, further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 22. A mammalian host cell for enhanced expression of IL2SA or fragment thereof, said-mammalian cell having genetic material coding for expression of IL2SA or fragment thereof and transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, hsp40, and Hsp70.
- 23. The mammalian host cell according to embodiment 22, wherein the genetic material coding for expression of IL2SA or fragment thereof is integrated into the host cell DNA.
- 24. The mammalian host cell according to embodiment 23, further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 25. A method for producing a mammalian host cell for enhanced expression of a target recombinant protein or fragment thereof comprising
providing a mammalian cell having genetic material coding for expression of a target recombinant protein or fragment thereof; and
transforming the mammalian cell with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70. - 26. The method according to embodiment 25 wherein the recombinant protein product is secreted.
- 27. The method according to embodiment 26, wherein the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- 28. The method according to embodiment 28, further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 29. The method according to embodiment 26, wherein the recombinant protein product is bikunin or fragment thereof.
- 30. The
method 1 according to embodiment 29, wherein the transforming occurs with an expression vector comprising DNA encoding calnexin. - 31. The method according to embodiment 29, wherein the transforming occurs with an expression vector comprising DNA encoding Erp57.
- 32. The method according to embodiment 29, wherein the transforming occurs with an expression vector comprising DNA encoding calreticulin.
- 33. The method according to embodiment 29, wherein the transforming occurs with an expression vector comprising DNA encoding Hsp70.
- 34. The method according to embodiment 26, wherein the recombinant protein product is Factor VIII or fragment thereof.
- 35. The method according to embodiment 34, wherein said transforming occurs with a first expression vector comprising DNA encoding calreticulin and a second expression vector comprising DNA encoding Erp57.
- 36. The method according to embodiment 34, wherein said transforming occurs with an expression vector comprising DNA encoding calnexin.
- 37. The method according to embodiment 34, wherein said transforming occurs with an expression vector comprising DNA encoding Hsp70.
- 38. The method according to embodiment 26, wherein the recombinant protein product is IL25A or fragment thereof.
- 39. The method according to embodiment 38, wherein said transforming occurs with an expression vector comprising DNA encoding Hsp70.
- 40. A method for producing a secreted recombinant protein product comprising the steps of:
- culturing a mammalian host cell, said mammalian host cell having genetic material coding for expression of said recombinant protein product and transformed with at least one expression vector comprising DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, hsp40, and Hsp70; and
- recovering from the culture medium the recombinant protein product so produced and secreted.
- 41. The method according to embodiment 40, wherein the genetic material coding for expression of said recombinant protein product is integrated into the host cell DNA.
- 42. The method according to embodiment 41, wherein said mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 43. A method for producing a bikunin protein or fragment thereof which comprises culturing the mammalian host cell according to
embodiment 5 and recovering from the culture medium the bikunin protein or fragment thereof so produced and secreted. - 44. The method according to embodiment 43, wherein said mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 45. A method for producing a Factor VIII protein or fragment thereof which comprises culturing the mammalian host cell according to
embodiment 10 and recovering from the culture medium the Factor VIII protein or fragment thereof so produced and secreted. - 46. The method according to embodiment 45, wherein said mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 47. A method for producing an IL2SA protein or fragment thereof which comprises culturing the mammalian host cell according to
embodiment 14 and recovering from the culture medium the IL2SA protein or fragment thereof so produced and secreted. - 48. The method according to embodiment 47, wherein said mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 49. A method for enhancing recombinant bikunin protein yield in a CHO cell line, wherein genetic material coding for expression of said recombinant bikunin has been previously introduced into a first CHO cell line, said method comprising the steps of:
- inserting at least one chaperone protein expression vector into said first CHO cell line so as to form a modified CHO cell line; and
- selecting from said modified CHO cell line at least one second cell line exhibiting enhanced yield of the recombinant bikunin protein.
- 50. The method according to embodiment 49, wherein the genetic material coding for expression of said recombinant bikunin is integrated into the first CHO cell DNA.
- 51. The method according to embodiment 50, wherein the second cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 52. The method according to embodiment 49, wherein at least one second cell line is produced from said first cell line by selecting a portion of said first cell line exhibiting integration of the chaperone protein expression vector into host DNA.
- 53. The method according to embodiment 49, wherein said chaperone protein expression vector comprises DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70.
- 54. The method according to embodiment 49, wherein said selection occurs in the presence of G418.
- 55. A method for enhancing recombinant Factor VIII yield in a baby hamster kidney (BHK) cell line, wherein genetic material coding for expression of said recombinant Factor VIII has been previously introduced into a first BHK cell line, said method comprising the steps of:
- inserting at least one chaperone protein expression vector into said first BHK cell line so as to form a modified BHK cell line; and
- selecting from said modified BHK cell line at least one second cell line exhibiting enhanced yield of the recombinant Factor VIII product.
- 56. The method according to embodiment 55, wherein the genetic material coding for expression of said recombinant Factor VIII is integrated into the first BHK cell DNA.
- 57. The method according to embodiment 55, wherein the second cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 58. The method according to embodiment 55, wherein at least one second cell line is produced from said first cell line by selecting a portion of said first cell line exhibiting integration of the chaperone protein expression vector into host DNA.
- 59. he method according to embodiment 55, wherein said chaperone protein expression vector comprises DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40 or Hsp70.
- 60. The method according to embodiment 55, wherein said BHK cell is further transfected with a vector including a puromycin-resistant gene.
- 61. The method according to embodiment 55, wherein the selection occurs in the presence of puromycin.
- 62. A method for enhancing recombinant IL2SA protein yield in a CHO cell line, wherein genetic material coding for expression of said recombinant IL2SA has been previously introduced into a first CHO cell line, said method comprising the steps of:
- inserting at least one chaperone protein expression vector into said first CHO cell line so as to form a modified CHO cell line; and
- selecting from said modified CHO cell line at least one second cell line exhibiting enhanced yield of the recombinant IL2SA protein.
- 63. The method according to
embodiment 62, wherein the genetic material coding for expression of said recombinant IL2SA is integrated into the first CHO cell DNA. - 64. The method according to embodiment 63, wherein the second cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 65. The method according to
embodiment 62, wherein said chaperone protein expression vector comprises DNA encoding a chaperone protein selected from the group consisting of calnexin, calreticulin, Erp57, Hsp40, and Hsp70. - 66. A method for enhancing yield of a recombinant bikunin or fragment in a CHO cell line comprising introducing genetic material coding for bikunin or fragment thereof into a CHO cell line exhibiting enhanced chaperone protein expression.
- 67. The method according to embodiment 66, wherein the CHO cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 68. A method for enhancing yield of a recombinant Factor VIII or fragment thereof in a BHK cell line comprising introducing genetic material coding for such Factor VIII or fragment thereof into a BHK cell line exhibiting enhanced chaperone protein expression.
- 69. The method according to embodiment 68, wherein the BHK cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- 70. A method for enhancing yield of a recombinant IL2SA or fragment thereof in a CHO cell line comprising introducing genetic material coding for such IL2SA into a CHO cell line exhibiting enhanced chaperone protein expression.
- 71. The method according to embodiment 70, wherein the CHO cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
-
- <110> Chan, Sham-Yuen Tang, Hsinyi Y Tao, Yiwen Wu, Yongjian Kelly, Ruth
- <120> Use of Molecular Chaperones for the Enhanced Production of Secreted, Recombinant Proteins in Mammalian Cells
- <130> 03-302-A
- <140>
10/792,571 - <150>
60/483,505 - <160> 22
- <170> PatentIn version 3.3
- <210> 1
<211> 28
<212> DNA
<213> Artificial sequence - <220>
<223> synthetic oligonucleotide - <400> 1
atgaattccg ggaggctaga gatcatgg 28 - <210> 2
<211> 28
<212> DNA
<213> Artificial sequence - <220>
<223> synthetic oligonucleotide - <400> 2
attctagatg caggggagga gggagaag 28 - <210> 3
<211> 28
<212> DNA
<213> Artificial sequence - <220>
<223> synthetic oligonucleotide - <400> 3
atgaattccc gccatgctgc tatccgtg 28 - <210> 4
<211> 28
<212> DNA
<213> Artificial sequence - <220>
<223> synthetic oligonucleotide - <400> 4
attctagact ggaggcaggc ctctctac 28 - <210> 5
<211> 28
<212> DNA
<213> Artificial sequence - <220>
<223> synthetic oligonucleotide - <400> 5
atgaattcct ccgcagtccc agccgagc 28 - <210> 6
<211> 28
<212> DNA
<213> Artificial sequence - <220>
<223> synthetic oligonucleotide - <400> 6
attctagact ctcggccctg agaggtaa 28 - <210> 7
<211> 1856
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (23)..(1801) - <400> 7
- <210> 8
<211> 592
<212> PRT
<213> Homo sapiens - <400> 8
- <210> 9
<211> 1287
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (12)..(1265) - <400> 9
- <210> 10
<211> 417
<212> PRT
<213> Homo sapiens - <400> 10
- <210> 11
<211> 1696
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (65)..(1582) - <400> 11
- <210> 12
<211> 505
<212> PRT
<213> Homo sapiens - <400> 12
- <210> 13
<211> 1926
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (1)..(1926) - <400> 13
- <210> 14
<211> 641
<212> PRT
<213> Homo sapiens - <400> 14
- <210> 15
<211> 1023
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (1)..(1023) - <400> 15
- <210> 16
<211> 340
<212> PRT
<213> Homo sapiens - <400> 16
- <210> 17
<211> 1122
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (1)..(1122) - <400> 17
- <210> 18
<211> 373
<212> PRT
<213> Homo sapiens - <400> 18
- <210> 19
<211> 170
<212> PRT
<213> Homo sapiens - <400> 19
- <210> 20
<211> 20
<212> DNA
<213> Artificial sequence - <220>
<223> synthetic oligonucleotide - <400> 20
agggaaccgc atggccaaag 20 - <210> 21
<211> 25
<212> DNA
<213> Artificial Sequence - <220>
<223> synthetic oligonucleotide - <400> 21
gaaaggcccc taatctacct cctca 25 - <210> 22
<211> 3
<212> PRT
<213> Artificial sequence - <220>
<223> synthetic peptide - <220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-benzoyl - <220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is Arg-pNA - <400> 22
Claims (18)
- A mammalian CHO host cell for enhanced expression of a recombinant bikunin protein, said mammalian CHO cell having genetic material coding for expression of said recombinant bikunin protein and transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- A mammalian BHK host cell for enhanced expression of a recombinant Factor VIII protein, said mammalian BHK cell having genetic material coding for expression of said recombinant Factor VIII protein and transformed with at least one expression vector comprising DNA encoding chaperone protein Erp57 and at least one expression vector comprising calreticulin.
- The mammalian host cell according to claim 1 or claim 2, wherein the recombinant protein is secreted.
- The mammalian host cell according to claim 3, wherein the genetic material coding for expression of said recombinant protein is integrated into host cell DNA.
- The mammalian host cell according to claim 4, further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- A method for producing a mammalian CHO host cell of claim 1, the method comprising:providing a mammalian CHO cell having genetic material coding for expression of recombinant bikunin protein; andtransforming the mammalian CHO cell with at least one expression vector comprising DNA encoding chaperone protein Erp57.
- A method for producing a mammalian BHK host cell of claim 2, the method comprising:providing a mammalian BHK cell having genetic material coding for expression of a recombinant Factor VIII protein; andtransforming the mammalian cell with at least one expression vector comprising DNA encoding chaperone protein Erp57 and at least one expression vector comprising DNA encoding chaperone protein calreticulin.
- The method according to claim 6 or claim 7, wherein the recombinant protein product is secreted.
- The method according to claim 8, wherein the genetic material coding for expression of said recombinant protein product is integrated into host cell DNA.
- The method according to claim 6 or claim 7, further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- A method for producing a secreted recombinant protein product comprising the steps of:culturing a mammalian host cell of claim 1 or claim 2; andrecovering from the culture medium the recombinant protein so produced and secreted.
- The method according to claim 11, wherein the genetic material coding for expression of said recombinant protein is integrated into the host cell DNA.
- The method according to claim 11, wherein said mammalian host cell is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- A method for enhancing recombinant bikunin protein yield, wherein genetic material coding for expression of said recombinant protein has been previously introduced into the cell line to form the first cell line, said method comprising the steps of:inserting at least one chaperone protein expression vector comprising DNA encoding Erp57 chaperone protein into said first cell line so as to form a modified cell line; andselecting from said modified cell line at least one second cell line exhibiting enhanced yield of the recombinant protein.
- A method for enhancing recombinant Factor VIII protein yield, wherein genetic material coding for expression of said recombinant protein has been previously introduced into a BHK cell line to form a first cell line, said method comprising the steps of:inserting at least one chaperone protein expression vector comprising DNA encoding Erp57 chaperone protein and DNA encoding CRT chaperone protein into said first cell line so as to form a modified cell line; andselecting from said modified cell line at least one second cell line exhibiting enhanced yield of the recombinant protein.
- The method according to claim 14 or claim 15, wherein the genetic material coding for expression of said recombinant protein is integrated into the first cell line DNA.
- The method according to claim 16, wherein the second cell line is further transformed with an expression vector comprising DNA encoding a glutamine synthetase protein.
- The method according to claim 14 or claim 15, wherein at least one second cell line is produced from said first cell line by selecting a portion of said first cell line exhibiting integration of the chaperone protein expression vector into host DNA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14162830.5A EP2808341B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48350503P | 2003-06-27 | 2003-06-27 | |
EP04801776.8A EP1641825B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04801776.8A Division EP1641825B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
EP04801776.8A Division-Into EP1641825B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
EP04801776.8 Division | 2004-03-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14162830.5A Division-Into EP2808341B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
EP14162830.5A Division EP2808341B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2338911A1 EP2338911A1 (en) | 2011-06-29 |
EP2338911B1 true EP2338911B1 (en) | 2015-05-06 |
Family
ID=34102653
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20100013146 Expired - Lifetime EP2338911B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
EP14162830.5A Expired - Lifetime EP2808341B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
EP04801776.8A Expired - Lifetime EP1641825B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14162830.5A Expired - Lifetime EP2808341B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
EP04801776.8A Expired - Lifetime EP1641825B1 (en) | 2003-06-27 | 2004-03-16 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
Country Status (6)
Country | Link |
---|---|
US (8) | US7244616B2 (en) |
EP (3) | EP2338911B1 (en) |
JP (2) | JP4712694B2 (en) |
CA (3) | CA2850891C (en) |
ES (3) | ES2634623T3 (en) |
WO (1) | WO2005010046A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244616B2 (en) | 2003-06-27 | 2007-07-17 | Bayer Pharmaceuticals Corporation | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
JP2005073621A (en) * | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | Marker for cerebral tumor and method for diagnosing cerebral tumor |
GB0329681D0 (en) * | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
EP2330200B1 (en) | 2004-12-23 | 2017-04-05 | Albumedix A/S | Gene expression technique |
GB0512707D0 (en) * | 2005-06-22 | 2005-07-27 | Delta Biotechnology Ltd | Gene expression technique |
ATE546464T1 (en) | 2006-04-21 | 2012-03-15 | Agency Science Tech & Res | METHOD FOR PRODUCING RECOMBINANT PROTEIN IN CHO CELLS |
MY148472A (en) * | 2007-03-02 | 2013-04-30 | Boehringer Ingelheim Pharma | Improvement of protein production |
EP2484371B1 (en) | 2008-06-26 | 2014-12-17 | Orphazyme APS | Use of Hsp70 as a regulator of enzymatic activity |
CA2736498C (en) * | 2008-09-11 | 2017-05-23 | Calretex, Llc | Compositions and methods for purifying calreticulin |
CA2817773A1 (en) | 2010-11-30 | 2012-06-07 | Orphazyme Aps | Methods for increasing intracellular activity of hsp70 |
KR101494072B1 (en) * | 2012-03-12 | 2015-02-17 | 한화케미칼 주식회사 | An expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a method for preparing a target protein employing the same |
EP2674495A1 (en) * | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
HUE061494T2 (en) | 2013-02-01 | 2023-07-28 | Selexis Sa | Enhanced transgene expression and processing |
US20170114382A1 (en) * | 2014-01-31 | 2017-04-27 | Biogen Ma Inc. | Methods of increasing protein production in mammalian cells |
CA2961097C (en) | 2014-09-15 | 2023-09-26 | Orphazyme Aps | Extended-release pharmaceutical formulation comprising arimoclomol |
WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
LT3448382T (en) | 2016-04-29 | 2021-04-12 | Orphazyme A/S | Arimoclomol for treating glucocerebrosidase associated disorders |
GB201708866D0 (en) | 2017-06-02 | 2017-07-19 | Univ Cape Town | Expression of chaperone proteins in planta for increased expression of heterologous polypeptides of interest |
KR102185312B1 (en) * | 2017-10-25 | 2020-12-02 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | A composition for solubilization of target proteins and use thereof |
CN109988777A (en) * | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | Glutamine synthetase gene and application |
SG11202107877WA (en) | 2018-06-21 | 2021-08-30 | NanoMed Holdings Pty Ltd | Platinum-based amphiphile prodrugs |
NZ800483A (en) | 2020-11-19 | 2024-03-22 | Zevra Denmark As | Processes for preparing arimoclomol citrate and intermediates thereof |
US20240166704A1 (en) | 2021-03-10 | 2024-05-23 | Sumitomo Pharma Co., Ltd. | Method for Producing Fusion Protein |
US20240150807A1 (en) * | 2021-03-10 | 2024-05-09 | Sumitomo Pharma Co., Ltd. | Method for Producing Cysteine Knot Protein |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649132A (en) | 1983-03-31 | 1987-03-10 | Scripps Clinic And Research Foundation | Treatment of Factor VIII inhibitors |
US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4912040A (en) * | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5149637A (en) | 1987-04-06 | 1992-09-22 | Scripps Clinic & Research Foundation | Recombinant Factor VIIIC fragments |
US5002874A (en) * | 1987-09-17 | 1991-03-26 | Genetics Institute, Inc. | Genetically engineered eucaryotic host cells capable of expressing modified forms of eIF-2α |
GB2237288A (en) * | 1989-10-18 | 1991-05-01 | Celltech Ltd | Amplification of a heterologous gene in recombinant eukaryotic host cells |
DE4113750A1 (en) * | 1991-04-26 | 1992-10-29 | Boehringer Mannheim Gmbh | IMPROVEMENT OF RENATURATION IN THE SECRETION OF DISULFID-BRIDGED PROTEINS |
US6291205B1 (en) | 1992-06-12 | 2001-09-18 | Merck & Co., Inc. | Method of increasing production of disulfide bonded recombinant proteins by saccharomyces cerevisiae |
DE69329202T2 (en) | 1992-10-02 | 2001-03-29 | Research Corp. Technologies, Inc. | METHODS OF INCREASING THE SECRETION OF OVEREXPRESSED PROTEINS |
US5455338A (en) * | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
JP3656277B2 (en) | 1995-05-17 | 2005-06-08 | 味の素株式会社 | Efficient production of transglutaminase by recombinant DNA method |
PL188387B1 (en) * | 1996-03-11 | 2005-01-31 | Bayer Ag | Human bikinine |
FR2755446B1 (en) | 1996-11-04 | 1999-01-08 | Inst Curie | STABLE CELL LINES EXPRESSING THE CFTR PROTEIN OR A MUTANT OF THIS PROTEIN, TOOL FOR THE SELECTION OF MOLECULES HAVING AN EFFECT ON THE INTRACELLULAR TRANSPORT OF THESE PROTEINS |
US6136599A (en) * | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
EP1374891B1 (en) | 1998-12-22 | 2008-09-10 | Bayer Aktiengesellschaft | Method for accelerating the rate of mucociliary clearance |
US6348192B1 (en) * | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
US6495360B1 (en) * | 1999-05-28 | 2002-12-17 | Photogen, Inc. | Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins |
US6476194B1 (en) * | 1999-06-29 | 2002-11-05 | National Research Council Of Canada | Method for folding unfolded proteins |
JP2003050104A (en) | 2001-08-07 | 2003-02-21 | Kyocera Corp | Optical sensor device in imaging device |
KR100476347B1 (en) * | 2002-09-30 | 2005-03-16 | 한국과학기술원 | Method for mass-production of target protein by regulating the expression of chaperone protein |
US7244616B2 (en) | 2003-06-27 | 2007-07-17 | Bayer Pharmaceuticals Corporation | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
US7226781B1 (en) * | 2003-07-24 | 2007-06-05 | Belyaev Alexander S | Chaperone expression genomes |
TWI567593B (en) | 2014-12-18 | 2017-01-21 | 明基電通股份有限公司 | Multi-functional mouse device and related method capable of automatically switching opertion modes |
US9703894B2 (en) | 2015-09-25 | 2017-07-11 | International Business Machines Corporation | Stored data with temporal proximity analysis for very large scale data with very low built in latency |
-
2004
- 2004-03-03 US US10/792,571 patent/US7244616B2/en not_active Expired - Lifetime
- 2004-03-16 ES ES14162830.5T patent/ES2634623T3/en not_active Expired - Lifetime
- 2004-03-16 ES ES10013146.5T patent/ES2538794T3/en not_active Expired - Lifetime
- 2004-03-16 CA CA2850891A patent/CA2850891C/en not_active Expired - Lifetime
- 2004-03-16 EP EP20100013146 patent/EP2338911B1/en not_active Expired - Lifetime
- 2004-03-16 CA CA2977618A patent/CA2977618A1/en not_active Abandoned
- 2004-03-16 CA CA2529369A patent/CA2529369C/en not_active Expired - Lifetime
- 2004-03-16 EP EP14162830.5A patent/EP2808341B1/en not_active Expired - Lifetime
- 2004-03-16 WO PCT/US2004/007993 patent/WO2005010046A1/en active Application Filing
- 2004-03-16 EP EP04801776.8A patent/EP1641825B1/en not_active Expired - Lifetime
- 2004-03-16 JP JP2006517077A patent/JP4712694B2/en not_active Expired - Lifetime
- 2004-03-16 ES ES04801776.8T patent/ES2514465T3/en not_active Expired - Lifetime
-
2007
- 2007-06-14 US US11/818,507 patent/US7951588B2/en active Active
-
2010
- 2010-06-23 JP JP2010143013A patent/JP5117542B2/en not_active Expired - Lifetime
-
2011
- 2011-05-25 US US13/115,417 patent/US8192985B2/en not_active Expired - Lifetime
-
2012
- 2012-05-04 US US13/464,543 patent/US8409857B1/en not_active Expired - Lifetime
-
2013
- 2013-03-06 US US13/786,614 patent/US20130189776A1/en not_active Abandoned
- 2013-03-13 US US13/799,564 patent/US8765466B2/en not_active Expired - Lifetime
- 2013-03-13 US US13/800,084 patent/US8772027B2/en not_active Expired - Lifetime
-
2014
- 2014-06-06 US US14/298,437 patent/US9284591B2/en not_active Expired - Lifetime
Non-Patent Citations (2)
Title |
---|
HEBERT D N ET AL: "Calnexin, calreticulin, and Bip/Kar2p in protein folding.", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY 1995, vol. 60, 1995, pages 405 - 415, ISSN: 0091-7451 * |
KLEIZEN BERTRAND ET AL: "Protein folding and quality control in the endoplasmic reticulum.", CURRENT OPINION IN CELL BIOLOGY AUG 2004, vol. 16, no. 4, August 2004 (2004-08-01), pages 343 - 349, ISSN: 0955-0674 * |
Also Published As
Publication number | Publication date |
---|---|
EP2808341A1 (en) | 2014-12-03 |
US20130330819A1 (en) | 2013-12-12 |
EP1641825B1 (en) | 2014-09-03 |
US20130189776A1 (en) | 2013-07-25 |
US9284591B2 (en) | 2016-03-15 |
CA2529369C (en) | 2014-07-15 |
US7244616B2 (en) | 2007-07-17 |
US8192985B2 (en) | 2012-06-05 |
ES2634623T3 (en) | 2017-09-28 |
ES2538794T3 (en) | 2015-06-24 |
JP4712694B2 (en) | 2011-06-29 |
US8765466B2 (en) | 2014-07-01 |
CA2850891C (en) | 2017-10-10 |
US20090104664A1 (en) | 2009-04-23 |
US8772027B2 (en) | 2014-07-08 |
US7951588B2 (en) | 2011-05-31 |
EP2338911A1 (en) | 2011-06-29 |
EP1641825A1 (en) | 2006-04-05 |
JP2010263903A (en) | 2010-11-25 |
JP2007524381A (en) | 2007-08-30 |
EP2808341B1 (en) | 2017-04-26 |
WO2005010046A1 (en) | 2005-02-03 |
CA2529369A1 (en) | 2005-02-03 |
US20150037841A1 (en) | 2015-02-05 |
JP5117542B2 (en) | 2013-01-16 |
ES2514465T3 (en) | 2014-10-28 |
US20120009670A1 (en) | 2012-01-12 |
US8409857B1 (en) | 2013-04-02 |
US20130330820A1 (en) | 2013-12-12 |
US20050048608A1 (en) | 2005-03-03 |
CA2850891A1 (en) | 2005-02-03 |
CA2977618A1 (en) | 2005-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9284591B2 (en) | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells | |
JP5432117B2 (en) | Recombinant expression vector element (rEVE) for enhancing expression of recombinant protein in a host cell | |
US20120040402A1 (en) | Plasmid system for multigene expression | |
Majors et al. | Enhancement of transient gene expression and culture viability using Chinese hamster ovary cells overexpressing Bcl‐xL | |
JP6861637B2 (en) | Eukaryotic expression vector containing regulatory elements of globin gene clusters | |
JP3861134B2 (en) | Protein expression methods and protein expression constructs | |
JP2002507894A (en) | Methods for increasing secretion of proteins in eukaryotic host cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1641825 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE ES FR GB IT |
|
17P | Request for examination filed |
Effective date: 20111222 |
|
17Q | First examination report despatched |
Effective date: 20120321 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/81 20060101ALI20140909BHEP Ipc: C12P 21/00 20060101ALI20140909BHEP Ipc: C12N 15/85 20060101ALI20140909BHEP Ipc: C07K 14/755 20060101AFI20140909BHEP Ipc: C12N 5/00 20060101ALI20140909BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20141017 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TANG, HSINYJ YVETTE Inventor name: CHAN, SHAM-YUEN Inventor name: TAO, YIWEN Inventor name: WU, YONGJIAN Inventor name: KELLY, RUTH |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER HEALTHCARE LLC |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1641825 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE ES FR GB IT |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602004047157 Country of ref document: DE Effective date: 20150618 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2538794 Country of ref document: ES Kind code of ref document: T3 Effective date: 20150624 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602004047157 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
26N | No opposition filed |
Effective date: 20160209 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602004047157 Country of ref document: DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230221 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230228 Year of fee payment: 20 Ref country code: GB Payment date: 20230216 Year of fee payment: 20 Ref country code: DE Payment date: 20230222 Year of fee payment: 20 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230507 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230406 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 602004047157 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20240315 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240315 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20240503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240317 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240317 |